A Phase 2 interventional study of Miricorlilant and Miricorlilant in Antipsychotic-induced Weight Gain (AIWG), sponsored by Corcept Therapeutics. Completed at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-13.
Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic medications.
This is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and PK of miricorilant in obese patients with schizophrenia who are currently taking olanzapine, risperidone, paliperidone, or quetiapine.
Patients who meet the criteria for the Study CORT118335-877 will be randomized on Day 1 to receive 600 mg miricorilant, 900 mg miricorilant, or placebo for 26 weeks.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 150 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 26 weeks.
Drug: Miricorlilant
Patients who meet the entry criteria will be randomized to receive 900 mg miricorilant for 26 weeks.
Drug: Miricorlilant
Patients who meet the entry criteria will be randomized to receive placebo for 26 weeks.
Drug: Placebo
Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing
Also known as: CORT118335
Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing
Also known as: CORT118335
Placebo for once-daily oral dosing
Change From Baseline in Body Weight
Time frame: Baseline Day 1 and Week 26
Change From Baseline in Body Weight for Both Dose Levels of Miricorilant Combined Versus Placebo
Time frame: Baseline Day 1 and Week 26
Percentage of Patients Achieving a ≥5% Weight Loss for Miricorilant Versus Placebo
Percentage of patients achieving a ≥5% weight loss for 600 mg miricorilant versus placebo and 900 mg miricorilant versus placebo
Time frame: Baseline Day 1 to Week 26
Change From Baseline in Waist-to-hip Ratio for Miricorilant Versus Placebo
Time frame: Baseline Day 1 and Week 26
Number of Patients With One or More Treatment-emergent Adverse Events
Time frame: Baseline Day 1 to Week 30
Number of Patients With One or More Treatment-emergent Serious Adverse Events
Time frame: Baseline Day 1 to Week 30
Number of Patients With One or More Treatment-emergent Adverse Events Leading to Study Drug Discontinuation
Time frame: Baseline Day 1 to Week 30
| Milestone | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Started | 50 | 48 | 52 |
| Completed | 33 | 37 | 34 |
| Not completed | 17 | 11 | 18 |
| Withdrew: Withdrawal by subject | 10 | 3 | 8 |
| Withdrew: Lost to follow-up | 3 | 4 | 3 |
| Withdrew: Adverse event | 3 | 1 | 4 |
| Withdrew: Non-compliant with study drug | 1 | 2 | 3 |
| Withdrew: Moved | 0 | 1 | 0 |
| kg | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight | -1.41 ± 0.644 | -0.91 ± 0.631 | -1.66 ± 0.644 |
| kg | Miricorilant 600 mg or 900 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight for Both Dose Levels of Miricorilant Combined Versus Placebo | -1.16 ± 0.454 | -1.65 ± 0.642 |
Percentage of patients achieving a ≥5% weight loss for 600 mg miricorilant versus placebo and 900 mg miricorilant versus placebo
| Participants | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Percentage of Patients Achieving a ≥5% Weight Loss for Miricorilant Versus Placebo | 12 | 7 | 8 |
| Ratio | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Waist-to-hip Ratio for Miricorilant Versus Placebo | 0.002 ± 0.0077 | 0.009 ± 0.0075 | 0.002 ± 0.0077 |
| Participants | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Number of Patients With One or More Treatment-emergent Adverse Events | 26 | 21 | 21 |
| Participants | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Number of Patients With One or More Treatment-emergent Serious Adverse Events | 1 | 2 | 2 |
| Participants | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Number of Patients With One or More Treatment-emergent Adverse Events Leading to Study Drug Discontinuation | 7 | 5 | 4 |
Collected over Baseline Day 1 to Week 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Miricorlilant 600 mg | 0/50 (0%) | 1/50 (2%) | 8/50 (16%) |
| Miricorlilant 900 mg | 0/48 (0%) | 2/48 (4.2%) | 3/48 (6.3%) |
| Placebo | 0/52 (0%) | 2/52 (3.8%) | 4/52 (7.7%) |
| Event | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 0/50 | 1/48 | 0/52 |
| Pulmonary massRespiratory, thoracic and mediastinal disorders | 0/50 | 1/48 | 0/52 |
| SchizophreniaPsychiatric disorders | 1/50 | 0/48 | 0/52 |
| Regressive behaviorPsychiatric disorders | 0/50 | 0/48 | 1/52 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/50 | 0/48 | 1/52 |
| Event | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo |
|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 4/50 | 1/48 | 0/52 |
| HeadacheNervous system disorders | 4/50 | 2/48 | 1/52 |
| Aspartate aminotransferase increasedInvestigations | 3/50 | 1/48 | 0/52 |
| DizzinessNervous system disorders | 1/50 | 1/48 | 3/52 |
All enrolled patients
| Age, Continuous(years) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 45.5 ± 10.80 | 46.4 ± 10.88 | 47.5 ± 10.27 | 46.5 ± 10.61 |
| Sex: Female, Male(Participants) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 17 | 19 | 18 | 54 |
| Male | 33 | 29 | 34 | 96 |
| Ethnicity (NIH/OMB)(Participants) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 9 | 8 | 4 | 21 |
| Not Hispanic or Latino | 40 | 40 | 48 | 128 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 28 | 29 | 28 | 85 |
| White | 19 | 17 | 21 | 57 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 0 | 1 | 3 |
| Region of Enrollment(participants) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 50 | 48 | 52 | 150 |
| Body weight(kg) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 115.41 ± 24.24 | 108.02 ± 19.78 | 118.11 ± 25.71 | 113.98 ± 23.69 |
| Waist-to-hip ratio(Ratio) | Miricorlilant 600 mg | Miricorlilant 900 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 0.991 ± 0.07 | 0.999 ± 0.06 | 0.992 ± 0.08 | 0.994 ± 0.07 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Jul 2022, 22 months.
Results were first posted in Jun 2024, 1 year 10 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 22 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CORT118335